PDI deal deploys 300 sales reps

Share this article:
PDI signed a deal with an undisclosed major pharmaceutical company to employ 300 sales reps and is expected to reap $35–$40 million, the contract sales force provider said.

The contract followed the April termination of the firm's agreement with AstraZeneca, which affected approximately 800 field reps and had a projected $60–$70 million impact.

“This particular ‘major pharmaceutical company' was not necessarily in the market for additional representatives but when they saw the fact that we had some reps trained in a specific category, the light bulb went off and they thought, ‘hey, we could use those people,'” said Stephen Cotugno, PDI EVP of corporate development.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.